Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes

Hao Peng1,2†, Lei Chen1,2†, Rui Guo1,2, Yuan Zhang1,2, Wen-Fei Li1,2, Yan-Ping Mao1,2, Ying Sun1,2, Fan Zhang1,2, Li-Zhi Liu1,3, Li Tian1,3 and Jun Ma1,2*

Abstract

Background: Nasopharyngeal carcinoma (NPC) shows a high proportion of lymph node metastasis, and treatment guidelines have been developed for positive nodes. However, no irradiation guidelines have been proposed for patients with enlarged neck lymph nodes (ENLNs) that do not meet the radiological criteria of 10 mm in diameter for positive lymph nodes. This study aimed to determine the prognostic value and radiation dose for ENLNs in N0-category NPC patients treated with intensity-modulated radiotherapy (IMRT).

Methods: We reviewed the medical data of 251 patients with non-metastatic, N0-category NPC treated with IMRT. Receiver operating characteristic curves were used to calculate the cut-off value of the ENLN diameter for the prediction of disease failure. The biological equivalent dose (BED) for ENLNs was calculated. Patient survival was compared between the small and large ENLN groups. Independent prognostic factors were identified using the Cox proportional hazards model.

Results: The estimated 4-year regional relapse-free survival rate was higher in patients with ENLNs ≥5.5 mm than in those with ENLNs <5.5 mm (100% vs. 98.8%, P = 0.049), whereas disease-free, overall, and distant metastasis-free survival rates were similar between the two groups. After adjusting for various factors, ENLN diameter was not identified as an independent prognostic factor (P > 0.05 for all survival rates). In the subgroup analysis, patients receiving BED ≥72 Gy had a similar prognosis as patients receiving BED <72 Gy in both the small and large ENLN groups. The multivariate analysis also confirmed that BED ≥72 Gy was not associated with significantly improved prognosis in patients with N0-category NPC.

Conclusions: A BED of 72 Gy to ENLNs is considerably sufficient to provide a clinical benefit to patients with N0-category NPC. Prospective studies are warranted to validate the findings in the present study.

Keywords: Nasopharyngeal carcinoma, N0-category, Enlarged neck lymph node, Biological equivalent dose, Intensity-modulated radiotherapy, Prognosis

*Correspondence: majun2@mail.sysu.edu.cn
†Hao Peng and Lei Chen contributed equally to this work
1 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong, P. R. China
Full list of author information is available at the end of the article

© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Nasopharyngeal carcinoma (NPC), a cancer arising from the nasopharyngeal epithelium, has an extremely unbalanced geographical distribution with an age-standardized incidence of 20–50 per 100,000 males in South China compared to 0.5 per 100,000 in predominantly white populations of European origin [1]. Due to the difficulty of radical resection and the high degree of radiosensitivity of NPC, radiotherapy has been the primary and only curative treatment for non-disseminated NPC. Chemotherapy has also been reported to provide a survival benefit to patients with advanced NPC [2]. For patients with lymph node (LN)-positive NPC, concurrent chemoradiotherapy (CCRT) alone or combined with neoadjuvant/adjuvant chemotherapy has been recommended as the standard treatment according to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines [3].

NPC has a high proportion of LN metastasis (86.4%) [4], and the NCCN guidelines recommend a prescribed dose of 66–70 Gy to treat positive LNs. However, no irradiation guidelines have been proposed for patients with enlarged neck LNs (ENLNs) that do not meet the radiological criteria of 10 mm in diameter for positive LNs [5]. Indeed, it is difficult to assess the nature of such ENLNs because NPC is typically treated using radiotherapy without performing cervical nodal biopsies. In clinical practice, this issue remains controversial as many clinicians concern that these ENLNs may be positive and adversely affect prognosis. However, other clinicians have considered ENLNs to be negative and treat these tumors with a low prescribed radiation dose. This situation urgently needs to be addressed.

To the best of our knowledge, no studies to date have investigated the prognostic value of ENLNs in patients with N0-category NPC treated with intensity-modulated radiotherapy (IMRT). Therefore, we conducted a retrospective study to characterize this issue and provide clinical evidence to help clinicians guide the treatment of NPC in such situations.

Methods
Ethical agreement
The present study was approved by the Research Ethics Committee of Sun Yat-sen University Cancer Center (Guangzhou, China), and informed consent was obtained from all patients for the use of their data in clinical researches. The present study was conducted in accordance with the ethical standards of the institution.

Patient selection
The data of patients with newly-diagnosed, non-disseminated NPC treated between November 2009 and February 2012 at Sun Yat-sen University Cancer Center were reviewed. Pre-treatment magnetic resonance imaging (MRI) data on the nasopharyngeal and cervical regions were thoroughly analyzed. The eligibility criteria were as follows: (1) N0-category disease; (2) World Health Organization (WHO) pathologic type II/III; and (3) age of 18 years or older.

Clinical staging
The routine staging process included a complete history collection and clinical examination of the head and neck region, direct fiberoptic nasopharyngoscopy, MRI scans of the skull base, neck and chest radiography, a whole-body bone scan, and abdominal sonography. Positron emission tomography (PET)-computed tomography (CT) scans were also performed when clinically indicated. All patients received a dental evaluation before radiotherapy.

All cases were restaged according to the 7th edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) system [6]. All MRI materials and clinical records were reviewed to minimize heterogeneity in restaging. Two radiologists (L.Z.L and L.T) separately evaluated all the scans, and disagreements were resolved by consensus.

MRI protocol
All patients underwent MRI using a 3-Tesla system (Trio Tim; Siemens, Erlangen, Germany). The region from the suprasellar cistern to the inferior margin at the sternal end of the clavicle was examined using a head-and-neck coil. T1-weighted fast spin-echo images on the axial, coronal, and sagittal planes (repetition time [TR]/echo time [TE], 650/9 ms), T2-weighted fast spin-echo images on the axial plane (TR/TE, 2470/90 ms), and a spin-echo echo-planar DWI sequence (matrix, 192 × 192; TR/TE, 5100/96 ms; b values, 0 and 1000 s/mm²; three signal averages) were obtained before contrast injection. After the intravenous administration of gadopentetate dimeglumine (0.1 mmol/kg body weight; Magnevist, Schering, Berlin, Germany), axial and sagittal T1-weighted spin-echo sequences and coronal T1-weighted fat-suppressed spin-echo sequences were performed sequentially using the same parameters as applied before the injection of gadopentetate dimeglumine. Subsequently, 5-mm-thick sections were obtained with a 1-mm interslice gap for the axial plane, and 6-mm-thick sections with a 1-mm interslice gap were obtained for the coronal and sagittal planes, resulting in a matrix size of 512 × 512.

Measurement of the short diameter of the ENLNs
T2-weighted axial MRI data without contrast enhancement were reviewed. The short diameters of the ENLNs were measured separately by two radiologists with experience of more than 10 years. Disagreements were resolved by consensus. For patients with two or more ENLNs, the...
short diameter of the largest ENLN was measured. The maximum short diameter should be ≤10 mm for ENLNs of level IIa and ≤9 mm for ENLNs of other levels.

Clinical treatment

Radiotherapy

All patients underwent IMRT at Sun Yat-sen University Cancer Center. Immobilization was achieved using a custom-made head-to-neck thermoplastic cast with the patient’s neck resting on a support. High-resolution planning CT scans with contrast were taken from the vertex to 2 cm below the sternoclavicular joint at a slice thickness of 3 mm. The target volumes were delineated slice-by-slice on treatment planning CT scans using an individualized delineation protocol according to the International Commission on Radiation Units and Measurements reports 50 and 62. All targets were treated using the simultaneous integrated boost technique. The biological equivalent dose (BED) for the ENLNs was calculated using the following formula:

$$\text{BED} = nd \times \left(1 + \frac{d}{[\alpha/\beta]}\right),$$

with $nd$ represents the total radiation dose, $d$ represents fraction dose, $\alpha/\beta$ represents the biological effect of tumor cells to radiation (the value for tumor tissues is 10) [7].

Chemotherapy

According to our institutional guidelines, prior to commencing the treatment, we recommended radiotherapy alone for stage I disease, CCRT for stage II disease, and CCRT alone or in combination with neoadjuvant/adjuvant chemotherapy for stage III to IVA-B disease. Neoadjuvant or adjuvant chemotherapy regimen comprised cisplatin (80 mg/m² on day 1) with 5-fluorouracil (750 mg/m² on days 1–5) or cisplatin (75 mg/m² on day 1) with docetaxel (75 mg/m² on day 1) every 3 weeks for two or three cycles. Concurrent chemotherapy regimen comprised cisplatin (30–40 mg/m² on day 1) administered every week or cisplatin (80–100 mg/m² on day 1) on weeks 1, 4, and 7 of radiotherapy.

Follow-up and statistical analysis

Patient follow-up was measured from the first day of therapy to the last visit (August 8, 2016) or death. The patients were examined at least every 3 months during the first 2 years and every 6 months thereafter until death. The end-points (time to first defining event) were regional relapse-free survival (RRFS, time to regional node recurrence), disease-free survival (DFS, time to disease recurrence or death), overall survival (OS, time to death from any cause), and distant metastasis-free survival (DMFS, time to distant metastasis); local relapse-free survival (LRFS) was not assessed in the present study. RRFS was the primary end-point of the present study.

Receiver operating characteristic (ROC) curves were used to calculate the cut-off value of the ENLN diameter for the prediction of DFS. The cut-off value of serum lactate dehydrogenase (LDH) level was determined as previously described [8, 9]. The Chi square test was used to compare clinical characteristics. Life-table estimation was performed using the Kaplan–Meier method and log-rank test. The multivariate Cox proportional hazards model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI). All statistical tests were two-sided; $P < 0.05$ was considered significant. STATA statistical package (STATA 12; StataCorp LP, College Station, Texas, USA) was used for all analyses.

Results

ENLN diameter

A total of 1811 patients were diagnosed with non-disseminated NPC at Sun Yat-sen University Cancer Center between November 2009 and February 2012, and 251 (13.9%) were selected in the present study. The median diameter of the largest ENLN for the 251 patients was 6 mm (range, 3–10 mm). Based on an analysis of the ROC curve (Fig. 1), the cut-off value of the ENLN diameter for the prediction of DFS was 5.5 mm (area under the curve [AUC], 0.569; sensitivity, 0.773; specificity, 0.349). Therefore, patients were divided into small and large ENLN groups using this cut-off value: 85 (33.9%)
patients had ENLN <5.5 mm, and 166 (66.1%) patients had ENLN ≥5.5 mm in the short diameter.

Baseline characteristics and radiation dose

Of the 251 patients, 194 (77.3%) were males, and 57 (22.7%) were females, with a male-to-female ratio of 3.4:1. The median age was 46 years (range, 19–77 years). The small and large ENLN groups were similar in terms of host factors, tumor stage, and treatment (all \( P > 0.05 \)) (Table 1).

The prescribed doses were 66–72 Gy at 2.12–2.43 Gy/fraction to the planning target volume (PTV) of the primary gross tumor volume (GTVnx), 50–68 Gy at 1.67–2.27 Gy/fraction to the PTV of the ENLN (GTVnd), 60–63 Gy to the PTV of the high-risk clinical target volume (CTV1), and 50–56 Gy to the PTV of the low-risk clinical target volume (CTV2). The median BED to GTVnd was 72.0 Gy (range, 58.3–83.4 Gy) for the entire cohort, 72.0 Gy (range, 58.3–83.4 Gy) for the small ENLN group, and 72.0 Gy (range, 58.3–82.0 Gy) for the large ENLN group. The BED was not significantly different between the small and large ENLN groups (\( t \)-test, \( P = 0.418 \)).

Treatment failure patterns

Up to the last follow-up (August 8, 2015), 16 (6.4%) patients were lost to follow-up. The median follow-up duration was 49.3 months (range, 11.0–67.7 months) for the entire cohort and 49.8 months (range, 11.3–67.7 months) for the surviving patients. In total, 10 (4.0%) patients developed local recurrence, 2 (0.8%) experienced regional recurrence, and 12 (4.8%) suffered distant metastasis. Moreover, 12 cancer-related deaths were observed. The failure patterns in the two groups are summarized in Table 2.

Univariate and multivariate analysis

For the entire cohort, the estimated 4-year RRFS, DFS, OS, and DMFS rates were 99.6, 91.4, 95.3, and 95.2%, respectively. For patients in the large and small ENLN groups, except for the estimated 4-year RRFS rate (100% vs. 98.8%, \( P = 0.049 \); Fig. 2a), the estimated 4-year DFS (89.4% vs. 95.2%, \( P = 0.246 \); Fig. 2b), OS (94.8% vs. 96.4%, \( P = 0.572 \); Fig. 2c), and DMFS rates (93.9% vs. 97.6%, \( P = 0.199 \); Fig. 2d) were comparable. Moreover, the 4-year RRFS (100% vs. 99.4%, \( P = 0.278 \)), DFS (95.4% vs. 91.4%, \( P = 0.062 \)), OS (97.7% vs. 94.0%, \( P = 0.311 \)), and DMFS rates (97.8% vs. 93.7%, \( P = 0.147 \)) were also comparable between patients receiving BED < and ≥72 Gy.

### Table 1 Baseline characteristics of the 251 patients with N0-category nasopharyngeal carcinoma (NPC) and enlarged neck lymph nodes (ENLNs)

| Characteristic                      | Total (cases) | Small ENLN group [cases (%)] | Large ENLN group [cases (%)] | \( P \) value\(^a\) |
|------------------------------------|---------------|------------------------------|------------------------------|-------------------|
| Gender                             |               |                              |                              | 0.923             |
| Male                               | 194           | 66 (77.6)                    | 128 (77.1)                   |                   |
| Female                             | 57            | 19 (22.4)                    | 38 (22.9)                    |                   |
| Age (years)                        |               |                              |                              | 0.661             |
| <50                                | 167           | 55 (64.7)                    | 112 (67.5)                   |                   |
| ≥50                                | 84            | 30 (35.3)                    | 54 (32.5)                    |                   |
| Smoking                            |               |                              |                              | 0.935             |
| Yes                                | 73            | 25 (29.4)                    | 48 (28.9)                    |                   |
| No                                 | 178           | 60 (70.6)                    | 118 (71.1)                   |                   |
| Drinking                           |               |                              |                              | 0.836             |
| Yes                                | 25            | 8 (9.4)                      | 17 (10.2)                    |                   |
| No                                 | 226           | 77 (90.6)                    | 149 (89.8)                   |                   |
| LDH (U/L)                          |               |                              |                              | 0.973             |
| <245                               | 242           | 82 (96.5)                    | 160 (96.4)                   |                   |
| ≥245                               | 9             | 3 (3.5)                      | 6 (3.6)                      |                   |
| Family history of cancer           |               |                              |                              | 0.332             |
| Yes                                | 87            | 26 (30.6)                    | 61 (36.7)                    |                   |
| No                                 | 164           | 59 (69.4)                    | 105 (63.2)                   |                   |
| BED (Gy)                           |               |                              |                              | 0.821             |
| <72                                | 91            | 30 (35.3)                    | 61 (36.7)                    |                   |
| ≥72                                | 160           | 55 (64.7)                    | 105 (63.3)                   |                   |
| Chemotherapy                       |               |                              |                              | 0.222             |
| Yes                                | 152           | 47 (55.3)                    | 105 (63.3)                   |                   |
| No                                 | 99            | 38 (44.7)                    | 61 (36.7)                    |                   |
| T category\(^b\)                   |               |                              |                              | 0.270             |
| T1                                 | 80            | 27 (31.8)                    | 53 (31.9)                    |                   |
| T2                                 | 54            | 24 (28.2)                    | 30 (18.1)                    |                   |
| T3                                 | 87            | 25 (29.4)                    | 62 (37.3)                    |                   |
| T4                                 | 30            | 9 (10.6)                     | 21 (12.7)                    |                   |

\(^a\) \( P \) values were calculated using the Chi square test or Fisher’s exact test if indicated.

\(^b\) According to the 7th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system.

### Table 2 Failure patterns in the small and large ENLN groups of NPC patients

| Failure pattern                  | Small ENLN group [cases (%)] | Large ENLN group [cases (%)] | \( P \) value\(^a\) |
|----------------------------------|------------------------------|------------------------------|-------------------|
| Local recurrence                 | 0 (0)                        | 10 (6.0)                     | 0.049             |
| Regional recurrence              | 2 (2.3)                      | 0 (0)                        | 0.217             |
| Total locoregional failure       | 2 (2.3)                      | 10 (6.0)                     | 0.328             |
| Distant metastasis               | 2 (2.3)                      | 10 (6.0)                     | 0.328             |
| Total death                      | 3 (3.5)                      | 9 (5.4)                      | 0.725             |
| Total failure                    | 5 (5.9)\(^b\)               | 17 (10.2)\(^c\)             | 0.248             |

\(^a\) \( P \) values were calculated using Chi square test or Fisher exact test if indicated.

\(^b\) One patient died without disease recurrence and distant metastasis.

\(^c\) Three patients experienced both local and distant failure.
Multivariate analysis was performed to adjust for various factors, including gender, age, smoking, drinking, serum LDH level, family history of cancer, BED, chemotherapy, T category, and ENLN diameter. Both ENLN diameter and BED were not established as independent prognostic factors for RRFS, DFS, OS, or DMFS (all $P > 0.05$). Moreover, no significant prognostic factor was identified for RRFS (Table 3).

**Subgroup analysis**

Furthermore, we conducted a stratified analysis to characterize the prognostic value of different BED in the small and large ENLN groups. The estimated 4-year RRFS, DFS, OS, and DMFS rates were comparable between patients receiving a BED $\geq 72$ Gy and $< 72$ Gy in both the small ENLN group (Fig. 3) and the large ENLN group (Fig. 4).

**Discussion**

In the present study, we found that ENLN diameter was not an independent prognostic factor for patients with N0-category NPC and ENLN and that a BED $\geq 72$ Gy to the ENLNs was not associated with significantly prolonged RRFS, DFS, OS, or DMFS in both small and large ENLN groups. Moreover, consistent with previous results [8, 9], LDH was the most important predictor of DFS, OS, and DMFS.

Previous studies reported that 13.6% [4] and 15% [10] of patients with NPC had no lymph node metastasis, similar to the results of the present study (13.9%). In the cohort examined in the present study, tumor stage and treatment-related factors were well balanced between the small and large ENLN groups, and univariate analysis revealed that the 4-year RRFS rate was significantly higher in the small ENLN group than in the large ENLN group ($P = 0.049$). However, after adjusting for various factors, multivariate analysis did not establish ENLN diameter as an independent predictor of RRFS. There are three potential reasons that may explain this result. First, the ENLNs are pathologically negative and have no prognostic impact. Second, the radiation dose received by the ENLNs may be sufficient to provide a radical treatment effect and, therefore, result in a satisfactory prognosis. Third, the relatively small sample size of each group may have resulted in a low statistical power. Indeed, reflecting the excellent regional control rates, no independent

---

**Fig. 2** Kaplan–Meier survival curves of patients with N0-category NPC and ENLN in the small ENLN ($<$5.5 mm) and large ENLN ($\geq$5.5 mm) groups. **a** Regional relapse-free survival; **b** disease-free survival; **c** overall survival; **d** distant metastasis-free survival. NPC nasopharyngeal carcinoma, ENLN small neck lymph node.
| Variable                              | RRFS |   |   | DFS |   |   | OS |   |   | DMFS |   |   |
|--------------------------------------|------|---|---|-----|---|---|----|---|---|------|---|---|
|                                      | HR   | 95% CI | P value | HR   | 95% CI | P value | HR   | 95% CI | P value | HR   | 95% CI | P value |
| Gender (male vs. female)             | <0.001 | – | 0.666 | 1.548 | 0.530–4.525 | 0.424 | 1089 | 0.223–5.307 | 0.916 | 1562 | 0.340–7.182 | 0.567 |
| Age (≥50 vs. <50 years)              | <0.001 | – | 0.583 | 2.318 | 0.998–5.386 | 0.051 | 7955 | 1.916–33.026 | 0.004 | 2821 | 0.892–8.919 | 0.077 |
| Smoking (yes vs. no)                 | 0.009 | – | 0.841 | 1.680 | 0.686–4.116 | 0.257 | 2608 | 0.713–9.536 | 0.147 | 2.393 | 0.759–7.544 | 0.136 |
| Drinking (yes vs. no)                | 0.001 | – | 0.870 | 0.350 | 0.047–2.632 | 0.308 | <0.001 | – | 0.980 | <0.001 | – | 0.985 |
| Serum LDH level (<245 vs. ≥245 U/L) | <0.001 | – | 0.857 | 4.689 | 1.370–16.050 | 0.014 | 15445 | 3.224–73.992 | 0.001 | 5.794 | 1.258–26.693 | 0.024 |
| Family history of cancer (yes vs. no)| 132.973 | – | 0.585 | 0.764 | 0.302–1.933 | 0.570 | 0.199 | 0.034–1.172 | 0.074 | 0.602 | 0.160–2.270 | 0.454 |
| BED (<72 vs. ≥72 Gy)                 | 107,046.092 | – | 0.485 | 2.438 | 0.882–7.226 | 0.108 | 3.097 | 0.697–13.754 | 0.137 | 2.741 | 0.60–12.526 | 0.193 |
| Chemotherapy (yes vs. no)            | <0.001 | – | 0.473 | 1.123 | 0.409–3.084 | 0.821 | 1.132 | 0.235–5.465 | 0.877 | 0.924 | 0.228–3.752 | 0.912 |
| T category (T1–2 vs. T3–4)           | <0.001 | – | 0.539 | 1.204 | 0.510–2.842 | 0.672 | 2.984 | 0.649–13.720 | 0.160 | 1.497 | 0.468–4.794 | 0.497 |
| ENLN diameter (<5.5 vs. ≥5.5 mm)     | <0.001 | – | 0.498 | 1.914 | 0.704–5.200 | 0.203 | 1.288 | 0.308–5.392 | 0.729 | 2.579 | 0.556–11.969 | 0.226 |

RRFS: regional relapse-free survival, DFS: disease-free survival, OS: overall survival, DMFS: distant metastases-free survival, HR: hazard ratio, CI: confidence interval, LDH: lactate dehydrogenase, BED: biological equivalent dose.

– No confidence interval.
predictor was identified for RRFS among this cohort of patients with N0-category NPC.

Notably, the retropharyngeal small LNs were not analyzed in the present study because they are adjacent to the primary tumor and are often treated as part of the primary tumor volume, even if they do not fit the diagnostic criteria for positive LNs in clinical practice. Therefore, almost all negative retropharyngeal small LNs received a radical radiation dose, which would have affected the results of the present study if these nodes were included in the analysis. A comparison of the failure patterns between groups revealed that the large ENLN group had a significantly higher rate of local failure than the small ENLN group. However, local relapse-free survival (LRFS) was not assessed as an endpoint in the present study because the ENLNs would not affect the local control. Therefore, we did not perform univariate analysis of the LRFS for the two groups.

Many studies have solely focused on the feasibility of omitting irradiation to the lower neck in N0-category NPC [11–14]. However, no studies have investigated the optimal radiation dose for the ENLNs. Notably, the doses prescribed to the ENLNs greatly varied in the present study, and the highest dose was 68 Gy—the radical radiation dose for positive LNs. This finding reflects clinicians’ concern that the ENLNs may be positive and could adversely affect prognosis, and should, therefore, receive a radical radiation dose. Subgroup analysis was conducted to further investigate the prognostic value of the BED for patients in different ENLN groups to establish the optimal BED for the ENLNs. We found that patients receiving a BED ≥72 Gy had a similar prognosis to patients receiving a BED <72 Gy in both the small and large ENLN groups, indicating that a total BED of 72 Gy may be sufficient for the ENLNs. Moreover, Li et al. [14] also revealed that the administration of 60 Gy in 30 fractions (BED = 72 Gy) to the suspicious node area did not lead to cervical node relapse, further supporting the results obtained in the present study. This finding should be of great importance to clinicians when devising individualized treatment strategies.

Based on the results of the present study, we provide credible evidence to reassure clinicians that the ENLNs do not negatively affect the prognosis of patients with N0-category NPC in the era of IMRT if a total BED of 72 Gy is achieved. The BED for the treatment of the

Fig. 3 Kaplan–Meier survival curves of N0-category NPC patients in the small ENLN group stratified by a biological equivalent dose (BED) < or ≥72 Gy. a Regional relapse-free survival; b disease-free survival; c overall survival; d distant metastasis-free survival. NPC nasopharyngeal carcinoma, ENLN enlarged neck lymph node
ENLNs should not exceed 72 Gy, as excessive radiation doses will cause acute toxicities, such as radiation-related dermatitis, and severe long-term toxicities, such as neck muscle atrophy [15].

Several limitations exist in the present study. First, the follow-up duration may be insufficient to observe a significant difference of OS since patients with N0-category disease had excellent prognoses. Therefore, we set RRFS as the first endpoint to address this issue because a median follow-up of 49.3 months was sufficient to determine the difference in RRFS. Second, the assessment of the ENLNs could only be performed reliably using MRI because, unlike other head and neck cancers, NPC is typically treated without pathologic analysis of the ENLNs. Third, the sample size and number of regional failure events in each group were relatively small. Moreover, due to incomplete medical records, several other important prognostic factors, including plasma Epstein-Barr virus DNA [16–22] and primary tumor volume [23, 24], could not be assessed in the present study. Therefore, further prospective clinical studies with larger cohorts that include additional prognostic factors are warranted to confirm the outcomes of the present study.

Conclusions
The present retrospective study provides evidence suggesting the treatment of patients with N0-category NPC and ENLNs. A total BED of 72 Gy to the ENLNs is considerably sufficient to provide a clinical benefit, and excessive radiation doses could be avoided to reduce acute and long-term toxicities. However, prospective randomized studies are warranted to validate the findings obtained in the present study.

Authors’ contributions
Conception and design of the study: HP, LC and JM. Acquisition of data: HP, RG, WFL, and YZ. Analysis and interpretation of the data: HP, LC, LZL, LT, RG and FZ. Writing and revision of the manuscript: YPM and YS. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by grants from the Health & Medical Collaborative Innovation Project of Guangzhou City, China (No. 201400000001), the Sun Yat-sen University Clinical Research 5010 Program (No. 201400000001), the Science and Technology Project of Guangzhou City, China (No. 14570006), the Planned Science and Technology Project of Guangdong Province, China (No. 2013B02010004). We thank Ai-Hua Lin for the assistance in statistics and data analysis.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets analyzed in this current study were available from the corresponding author on reasonable request.

Received: 2 June 2016 Accepted: 19 October 2016
Published online: 24 March 2017
References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

2. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16(4):1310–7.

3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version 1.2016. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 6 May 2016.

4. Wang X, Hu C, Ying H, He X, Zhu G, Kong L, et al. Patterns of lymph node metastasis from nasopharyngeal carcinoma based on the 2013 updated consensus guidelines for neck node levels. Radiother Oncol. 2015;115(1):41–5.

5. van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology. 1990;177(2):379–84.

6. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.

7. Lee AW, Foo W, Law SC, Poon YF, Sze WM, et al. Patterns of lymph node metastasis from nasopharyngeal carcinoma treated using intensity-modulated radiation therapy for meta-regression analysis. Radiother Oncol. 2011;103(2):105–12.

8. Li G, Gao J, Tao XL, Xu BQ, Yu ZW, Liu ZG, et al. Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma. Chin J Cancer. 2015;34(6):247–53.

9. Wan XB, Wei L, Li H, Dong M, Lin Q, Ma XK, et al. Patterns of lymph node metastasis from nasopharyngeal carcinoma based on the 2013 updated consensus guidelines for neck node levels. Radiother Oncol. 2015;115(1):41–5.

10. He X, Pan Z, Guo X, Ye M, Zhang Z, He S, et al. The pattern of relapse and survival of elective irradiation of the upper neck for stage N0 nasopharyngeal carcinoma. Radiother Oncol. 2012;7:35.

11. Gao Y, Zhu G, Lu J, Ying H, Kong L, Wu Y, et al. Is elective irradiation to the lower neck necessary for N0 nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys. 2010;77(5):1397–402.

12. He X, Pan Z, Guo X, Ye M, Zhang Z, He S, et al. The pattern of relapse and survival of elective irradiation of the upper neck for stage N0 nasopharyngeal carcinoma. Radiother Oncol. 2012;7:35.

13. Zeng L, Sun XM, Chen CY, Han F, Huang Y, Xiao WW, et al. Comprehensive study on prophylactic irradiation to the whole neck and to the upper neck for patients with neck lymph node-negative nasopharyngeal carcinoma. Head Neck. 2014;36(5):687–93.

14. Li JG, Yuan X, Zhang LL, Tang YQ, Liu L, Chen XD, et al. A randomized clinical trial comparing prophylactic upper versus whole-neck irradiation in the treatment of patients with node-negative nasopharyngeal carcinoma. Cancer. 2013;119(17):3170–6.

15. Zhang LL, Wang XJ, Zhou GQ, Tang LL, Lin AH, Ma J, et al. Dose-volume relationships for moderate or severe neck muscle atrophy after intensity-modulated radiotherapy in patients with nasopharyngeal carcinoma. Sci Rep. 2015;5:18415.

16. An X, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011;117(16):3750–7.

17. Chan KC. Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma. Chin J Cancer. 2014;33(12):598–603.

18. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350(24):2461–70.

19. Lin JC, Wang WY, Liang WM, Chou HY, Jan JS, Jiang RS, et al. Long-term prognostic effects of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;68(5):1342–8.

20. Lo YM, Chan LT, Chan AT, Leung SF, Lo KW, Zhang J, et al. Temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999;59(21):5452–5.

21. Twu CW, Wang WY, Liang WM, Jan JS, Jiang RS, Chao J, et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;67(1):130–7.

22. Peng H, Guo R, Chen L, Zhang Y, Li WF, Mao YP, et al. Prognostic impact of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy. Sci Rep. 2016;6:22000.

23. Guo R, Sun Y, Yu XL, Yin WJ, Li WF, Chen YY, et al. Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol. 2012;104(3):294–9.

24. Tian YM, Xiao WW, Bai L, Liu JW, Zhao C, Lu TX, et al. Impact of primary tumor volume and location on the prognosis of patients with locally recurrent nasopharyngeal carcinoma. Chin J Cancer. 2015;34(6):247–53.